Yongli Zhang

Prof. Dr. Yongli Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2023 in Pharmacological Research
Verified
Journal Article
Open access
HLHuaguo Liang
Huaguo Liang
QHQingsong Huang
Qingsong Huang
LZLi Zou
Li Zou
PWPeng Wei
Peng Wei
JLJiazheng Lu
Jiazheng Lu
YZYongli Zhang
Yongli Zhang
Methyl gallate (MG) is a polyphenolic compound widely found in natural plants. MG has been shown to have a variety of biological functions, including anti-tumor, anti-inflammatory, anti-oxidant, neuroprotective, hepatoprotective and anti-microbial activities, and has broad research and development prospects. A total of 88 articles related to MG were searched using the PubMed, Science Direct, and Google Scholar databases, systematically investigating the pharmacological activity and molecular mechanisms of MG. There were no restrictions on the publication years, and the last search was conducted on June 5, 2023. MG can exert pharmacological effects through multiple pathways and targets, such as PI3K/Akt, ERK1/2, Caspase, AMPK/NF-κB, Wnt/β-catenin, TLR4/NF-κB, MAPK, p53, NLRP3, ROS, EMT. According to the literature, MG has the potential to be a prospective adjuvant for anticancer therapy and deserves further study.

6 March 2022 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
WCWanting Chen
Wanting Chen
QLQian Li
Qian Li
RHRanran Hou
Ranran Hou
HLHuaguo Liang
Huaguo Liang
YZYongli Zhang
Yongli Zhang
YYYongxia Yang
Yongxia Yang

31 July 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
JLJianxiong Li
Jianxiong Li
ZCZexin Chen
Zexin Chen
WXWentao Xiao
Wentao Xiao
HLHuaguo Liang
Huaguo Liang
YLYanan Liu
Yanan Liu
FWFengxiang Wei
Fengxiang Wei
Epithelial ovarian cancer (EOC) is one of the most prevalent gynaecological cancers worldwide. The molecular mechanisms of serous ovarian cancer (SOC) remain unclear and not well understood. SOC cases are primarily diagnosed at the late stage, resulting in a poor prognosis. Advances in molecular biology techniques allow us to obtain a better understanding of precise molecular mechanisms and to identify the chromosome instability region and key driver genes in the carcinogenesis and progression of SOC. Whole‐exome sequencing was performed on the normal ovarian cell line IOSE80 and the EOC cell lines SKOV3 and A2780. The single‐nucleotide variation burden, distribution, frequency and signature followed the known ovarian mutation profiles, without chromosomal bias. Recurrently mutated ovarian cancer driver genes, including LRP1B, KMT2A, ARID1A, KMT2C and ATRX were also found in two cell lines. The genome distribution of copy number alterations was found by copy number variation (CNV) analysis, including amplification of 17q12 and 4p16.1 and deletion of 10q23.33. The CNVs of MED1, GRB7 and MIEN1 located at 17q12 were found to be correlated with the overall survival of SOC patients (MED1: p = 0.028, GRB7: p = 0.0048, MIEN1: p = 0.0051), and the expression of the three driver genes in the ovarian cell line IOSE80 and EOC cell lines SKOV3 and A2780 was confirmed by western blot and cell immunohistochemistry.

6 April 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JLJianxiong Li
Jianxiong Li
HLHuaguo Liang
Huaguo Liang
WXWentao Xiao
Wentao Xiao
PWPeng Wei
Peng Wei
HCHongmei Chen
Hongmei Chen
YZYongli Zhang
Yongli Zhang
Background: Ovarian cancer is one of the most lethal cancers in women because it is often diagnosed at an advanced stage. The molecular markers investigated thus far have been unsatisfactory. Methods: We performed whole-exome sequencing on the human ovarian cancer cell lines 3AO and ES2 and the normal ovarian epithelial cell line IOSE-80. Molecular markers of ovarian cancer were screened from shared mutation genes and copy number variation genes in the 6q21-qter region. Results: We found that missense mutations were the most common mutations in the gene (93%). The MUC12, FLG and MUC16 genes were highly mutated in 3AO and ES2 cells. Copy number amplification occurred mainly in 4p16.1 and 11q14.3, and copy number deletions occurred in 4q34.3 and 18p11.21. A total of 23 hub genes were screened, of which 16 were closely related to the survival of ovarian cancer patients. The three genes CCDC170, THBS2 and COL14A1 are most significantly correlated with the survival and prognosis of ovarian cancer. In particular, the overall survival of ovarian cancer patients with high CCDC170 gene expression was significantly prolonged (P < 0.001). The expression of CCDC170 in normal tissues was significantly higher than that in ovarian cancer tissues (P < 0.05), and its expression was significantly decreased in advanced ovarian cancer. Western blotting and immunofluorescence assays also showed that the expression of CCDC170 in ovarian cancer cells was significantly lower than that in normal cells (P < 0.001, P < 0.01). Conclusions: CCDC170 is expected to become a new diagnostic molecular target and prognostic indicator for ovarian cancer patients, which can provide new ideas for the design of antitumor drugs.

1 January 2022 in Pharmacognosy Magazine
Verified
Journal Article
Closed access
PDF file
YZYongli Zhang
Yongli Zhang
YYYongxia Yang
Yongxia Yang
HLHuaguo Liang
Huaguo Liang
PZPei Zeng
Pei Zeng
WFWei Fu
Wei Fu
ACAli Chen
Ali Chen
Background: Luteolin (Lut) is a natural flavonoid with low water solubility. Many studies have revealed that its antitumor effect is more understandable. Objectives: Synthesis of glycyrrhizin-coupled bovine serum albumin-loaded Lut nanoparticles (GL-BSA-Lut-Nps) to progress the water solubility, anticancer effect, liver targeting, cycle arrest, induction apoptosis, and regulating the metabolism of Lut. Materials and Methods: The activity screening of GL-BSA-Lut-Nps on Hepatocellular Carcinoma Bel-7402 cells was spotted by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, cell cycle, and apoptosis were measured by flow cytometry. The solubility of GL-BSA-Lut-Nps was evaluated by ultraviolet spectrophotometer. Fluorescein isothiocyanate was employed to label the drug, and the fluorescence intensity of cells after drug uptake was detected under a fluorescence microscope to sense the targeting of GL-BSA-Lut-Nps to tumor cells. The differences of metabolites between Bel-7402 cells treated with GL-BSA-Lut-Nps and the control group were considered by 1 hydrogen-nuclear magnetic resonance metabolomics. Results: The results presented that the GL-BSA-Lut-Nps prepared by solvent removal method had good anti-tumor activity and water solubility in vitro and the No. 4 Lut nanoparticles (GL-BSA-Lut-Nps-4) screened by the MTT method had the best effect. The IC50 of the GL-BSA-Lut-Nps-4 on the Bel-7402 cell inhibition test was 1.999 ± 0.880 mg/mL. The results of cell cycle and apoptosis displayed that the anticancer effect of the prescription is more palpable. The results of the fluorescence original method are proposed to confirm that the experimentally created GL-BSA-Lut-Nps-4 have a liver targeting effect. The study of metabolomics further clarified the metabolic regulation effect of GL-BSA-Lut-Nps-4 on Bel-7402 cells. Conclusion: It delivers a theoretical basis for the development of new high-efficiency and low-toxicity traditional Chinese medicine preparations for liver cancer.

29 September 2025 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
CZChangtao Zheng
Changtao Zheng
LCLuzhu Chen
Luzhu Chen
XLXiaotian Lv
Xiaotian Lv
YHYaoyao He
Yaoyao He
XHXiangyun Hu
Xiangyun Hu
YZYongli Zhang
Yongli Zhang
Serous ovarian cancer (SOC) is one of the most important diseases affecting women’s health in the world. It is highly occult and often detected in late stage due to the lack of specific molecular markers. Whole exon sequencing was performed on 38 serous ovarian cancer samples, and the mutated gene PRTN3 was selected by bioinformatics analysis. In vitro experiments with serous ovarian cancer cell lines SKOV3 and OVCAR8 and normal ovarian epithelial cell line IOSE80 were performed to verify the expression of PRTN3 and the effect of its inhibitor sivelestat. Xenotransplantation models in vivo also confirmed the effect of sivelestat. We found that Missense Mutation accounted for the vast majority of somatic mutations, and 263 candidate mutant genes were obtained from the mutation frequency, among which three hub gene clusters centered on SF3A2, MUC3A, and PRTN3 were identified, and PRTN3 had the strongest effect on the overall survival of the patients. Subsequently, we verified the expression of PRTN3 in serous ovarian cancer samples and cell lines, PRTN3 was highly expressed in serous ovarian cancer samples and cell lines, and sivelestat could inhibit the migration ability of serous ovarian cancer cell lines. SKOV3 cells were used to construct xenografted tumor models to explore the prospect of PRTN3 as a molecular therapeutic target for ovarian cancer and the application potential of sivelestat, which can inhibit the progression of xenografted tumors in vivo with certain safety. Whole exome sequencing and bioinformatics analysis identified PRTN3 as a potential molecular marker of serous ovarian cancer, and PRTN3 could significantly affect the prognosis of SOC patients. As an inhibitor of PRTN3, sivelestat can inhibit the expression of PRTN3 in SOC cell lines and reduce their migration ability in vitro. In vivo experiments showed that sivelestat can inhibit the growth of subcutaneous transplanted tumor in nude mice with certain safety.